Friday, December 30, 2011
Thursday, December 29, 2011
"The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," he said. "All of them were highly sensitive to MK1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."
Wednesday, December 28, 2011
Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint
Tuesday, December 27, 2011
[zinc-binding motif (where X is any amino acid) in MMPs, a symmetrical tripodal tris-imidazol–zinc complex (Zn-tripod; ZnC36H59N11O8)]
New Antibodies Treat Autoimmune Disease in Mice
Ref : http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2582.html
Monday, December 26, 2011
"J147 enhances memory in both normal and Alzheimer's mice and also protects the brain from the loss of synaptic connections," says David Schubert, the head of Salk's Cellular Neurobiology Laboratory, whose team developed the new drug. "No drugs on the market for Alzheimer's have both of these properties."
Sunday, December 25, 2011
"The notch inhibitor appears to be doing what it is intended to do," said Dr. Clodia Osipo....
Saturday, December 24, 2011
Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
Thursday, December 22, 2011
Tuesday, December 20, 2011
Sunitinib IxabepiloneRef : http://www.mayoclinic.org/news2011-jax/6573.html
Sunday, December 18, 2011
Saturday, December 17, 2011
"This combination appears to deliver everything we expected and more," said Jakubowiak, who came to the University of Chicago this fall from the University of Michigan. "We have seen excellent efficacy — the best reported to date — without the neurotoxicity that has been problematic with other drug combinations."
Ref : http://www.uchospitals.edu/news/2011/20111206-myeloma.html
Friday, December 16, 2011
Thursday, December 15, 2011
Wednesday, December 14, 2011
"The studies confirmed the drug is very effective. As a representative of a particular class of molecular inhibitors called JAK2 inhibitors, which are now being widely studied, ruxolinitib suggests this category will continue to be promising for myelofibrosis," Dr. Mesa says.
Monday, December 12, 2011
Friday, December 9, 2011
Tuesday, December 6, 2011
Friday, December 2, 2011
Monday, November 28, 2011
European Commission approves Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Sunday, November 27, 2011
HSC NEWS - Bat plant could give some cancers a devil of a time
Saturday, November 26, 2011
Thursday, November 24, 2011
“It would be premature to make a recommendation that women drink coffee to lower their endometrial cancer risk,” study author Dr. Edward Giovannucci, professor of nutrition and epidemiology at Harvard School of Public Health...
Ref : http://cebp.aacrjournals.org/content/early/2011/10/03/1055-9965.EPI-11-0766.abstract?sid=d8d229ed-e4b4-4b7a-bc6a-f3f86cba4c0e
Wednesday, November 23, 2011
Sunday, November 20, 2011
Saturday, November 19, 2011
Friday, November 18, 2011
In continuation of my update on taxol....
Baran's group reports erecting that Rockefeller tree and adding the first few ornaments -- a molecule called taxadiene. A conventional taxadiene synthesis is inefficient and involves 26 steps to produce. The Baran group's method involves just 10 steps to produce many times what has been previously synthesized -- more than sufficient for planned research to find a way to efficiently produce Taxol®.
Innovation Leads to Access.....
The taxadiene synthesis is more than just a midway stop on the way to Taxol®. The current commercial Taxol® production method, which involves culturing cells from the yew tree, is more economical than any new synthesis is likely to be. Instead, Baran and his team are aiming to understand the processes used in nature to produce the compound, which are many times more efficient than those used by scientists to date. "It's my opinion that when there's a huge discrepancy between the efficiency of nature and humans, in the space between, there's innovation.
More specifically, lead researcher Phil Baran believes that, while developing an efficient synthesis for Taxol®, they will gain a fundamentally improved understanding of the chemistry involved and develop more widely applicable techniques. Such innovation could allow production of a whole range of taxanes currently inaccessible for drug discovery research either because the quantities researchers can produce are vanishingly small, or because they can't produce them at all. Control of the taxane oxidation process therefore offers the potential for discovering new and important drugs, perhaps even one or more that is better at fighting specific cancers than Taxol®.
Establishing the remaining steps between taxadiene and Taxol® or other more complex taxanes remains a challenging task that Baran estimates will take years.
"Nature has a choreography in the way she decorates the tree," he said. "It's a precise dance she has worked out over millennia. We have to figure out a way to bring that efficiency to the laboratory setting."
Tuesday, November 15, 2011
Sunday, November 13, 2011
Tuesday, November 8, 2011
Lead researcher Power said. "Myelin is insulation around nerves. MS is characterized by inflamed brain cells that have lost this protective insulation, which ultimately leads to neurodegeneration.......
Sunday, November 6, 2011
Probiotics effective in combating antibiotic-associated diarrhea, studies find; 'Good bugs' look promising as anti-inflammatory agents
Ref : http://www.nature.com/ajg/journal/v106/n10/full/ajg2011201a.html
Saturday, November 5, 2011
Friday, November 4, 2011
Thursday, November 3, 2011
Wednesday, November 2, 2011
Tuesday, November 1, 2011
Monday, October 31, 2011
Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival...
"These data are significant because they demonstrate that regorafenib increased overall survival in patients with heavily pretreated metastatic colorectal cancer, an area of high unmet medical need," said Kemal Malik .....
Ref : http://www.bayer.com/en/news-detail.aspx?newsid=15124
"Researchers analyzed the genomic defense pathways in plants to identify all the precursors to infection and used the information to discover a group of novel small molecules that interrupt one channel in the intricate pathway system."..
Saturday, October 29, 2011
Saturday, October 22, 2011
Friday, October 21, 2011
In this study, Idera created 19mer GSOs for apolipoprotein B (ApoB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA and evaluated their in vivo activity in mice following subcutaneous administration. The data demonstrate that treatment with each GSO led to a significant reduction in the concentration of the target associated mRNAs and protein. The effects were specific, with no significant effects being observed on ABCA1, ABCG1 or LXR mRNA levels. In addition, treatment with GSOs for either ApoB or PCSK9 resulted in a decrease in total serum cholesterol and LDL-cholesterol.
Wednesday, October 19, 2011
Tuesday, October 18, 2011
Saturday, October 15, 2011
Friday, October 14, 2011
Tuesday, October 11, 2011
Monday, October 10, 2011
Thursday, October 6, 2011
Wednesday, October 5, 2011
Tuesday, October 4, 2011
Thursday, September 29, 2011
"It improves the course of disease and, in my opinion, it's the first drug to significantly ameliorate the really devastating progression of the disease,"
Wednesday, September 28, 2011
Austrailian researchers examined the diets of 918 colorectal cancer patients and 1,021 people with no history of the disease and found that consumption of certain vegetables and fruits were associated with a decreased risk of cancer in the proximal and distal colon, that is, the upper and lower portions of the colon.
Thursday, September 22, 2011
Wednesday, September 21, 2011
- The frequency of treatment related adverse events for budesonide MMX 6 mg (21.0%) was similar to placebo (21.3%).
- Mean morning plasma Cortisol levels remained within normal limits at all visits for both budesonide MMX 6 mg and placebo.
- There were no clinically meaningful differences in the numbers of patients with abnormal bone mineral density scans at baseline and end-of-study between budesonide MMX 6 mg and placebo.
"Now that we have the top-line safety data from the extended use study, we are moving forward as planned to submit the NDA in December 2011 for budesonide MMX 9 mg for the induction of remission of mild to moderate active ulcerative colitis," said Gerald T. Proehl, CEO/President of the company...More.: http://ir.santarus.com/releasedetail.cfm?ReleaseID=606515